Trial reportAnnals of surgical oncology2026
Prospective Clinical Trial on Expanding the Eligibility Criteria for Targeted Axillary Dissection after Neoadjuvant Systemic Therapy in Breast Cancers with Advanced Nodal Disease.
Trial report in Annals of surgical oncology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
3 citing papers in PubMed.
- ASO Author Reflections: It's Not "Just" a Distal Pancreatectomy: The Impact of Postoperative Complications on Adjuvant Therapy Delivery in Left-Side Pancreatic Cancer.Annals of surgical oncology · 2026Article
- Expanding Eligibility for Targeted Axillary Dissection.Annals of surgical oncology · 2026Article
- Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundTargeted axillary dissection (TAD) is an established axillary restaging approach in breast cancer after neoadjuvant chemotherapy (NAC), but evidence to date has focused largely on clinical N1 disease with limited nodal involvement. For higher nodal burden patients, axillary dissection (AD) is still frequently performed despite high axillary pathologic complete response (pCR) rates. We hypothesized that TAD is noninferior to AD for nodal staging in patients with advanced nodal disease. PATIENTS AND
methodsPatients with higher nodal burden breast cancer planned for NAC followed by curative surgery were included. Higher nodal burden was defined as > 3 metastatic nodes up to clinical N3 stage. Patients underwent TAD followed by AD during the same operation. The primary outcome was the false negative rate (FNR) of TAD. Secondary outcomes included clipped node detection rate, concordance between clipped and sentinel nodes, and axillary pCR rates.
resultsA total of 65 patients were prospectively recruited from February 2023 to October 2025; 10 withdrew, leaving 55 for analysis. The technical success rate of TAD was 96%, with clipped node detection rate of 100% and sentinel node detection rate of 96%. The clipped node was identified as an additional sentinel node in 68%. Axillary pCR occurred in 49%. In non-pCR patients, TAD demonstrated a FNR of 0%.
conclusionsIn clinical N1 (> 3 nodes), N2, and N3 patients, a 0% FNR suggests TAD is highly accurate for detecting residual axillary disease in the setting of higher nodal burden. These results support expanding TAD eligibility in appropriately selected patients to potentially reduce AD and its morbidities.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.